This Month
Aussie high-flyer’s wings clipped by US investors
Red-hot biotech Telix got a shock when US investors wanted a chunky discount to buy stock. So it’s walking away looking silly, but with its pride intact.
- Anthony Macdonald
Telix pulls $300m Nasdaq IPO as investors demand deep discount
The cancer treatment hopeful had announced plans to list in New York only last week as it searched for more capital. On Friday, it withdrew from the initial public offering.
- Kylar Loussikian
Eight tips to lose weight fast - and safely
Is the crash diet back? Science now suggests that rapidly losing a lot of weight could be a beneficial strategy for health – if you do it carefully.
- Juliette Kellow
- Exclusive
- Mergers & acquisitions
Competition concerns stalk Chemist Warehouse’s $8.8b Sigma deal
A Singaporean hedge fund warns the “smart money was playing dumb” on a deal that means the merged group will be the only major player in Darwin and control 68 per cent of Melbourne’s market.
- Jemima Whyte and Jonathan Shapiro
Hanwha tussles with Austal board over ‘unfair’ diligence conditions
Austal’s would-be acquirer reckons that its third indicative bid was at least 15 per cent higher than that of Cerberus Capital Management.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
How to dementia-proof your life in your 40s
Research shows that this decade plays a crucial role in predicting your future brain health – and nobody knows why.
- Charlotte Lytton
- Exclusive
- Funding
Aussie vaccine start-up scores $300m valuation
GPN Vaccines has raised $18 million in a round led by Forepont Capital and Kern Capital.
- Yolanda Redrup
Vitamins group Homart brings in Ords, CLSA as it preps for ASX float
As it heads toward the bourse it is bulking up, acquiring New Zealand group Thompson’s Herbals and Thursday Plantation, a natural essential oils business.
- Simon Evans
- Exclusive
- Healthcare
GenesisCare’s valuation shrinks to less than $500m after bankruptcy
Once a global cancer services giant, the company’s new owners are buying back shares from local backers for just $0.000186 as the business is restructured.
- Carrie LaFrenz
- Exclusive
- Insolvency
Doctor told everything fine weeks before service provider collapsed
The founder of collapsed medical telehealth and legal advisory service provider eReports claimed his business would be trading for “many years to come”.
- Max Mason
Chris Abbott-backed Genetic Signatures raises $30 million
There’s an FDA approval in the bag, and a CEO replacement for long-standing boss John Melki has been found. And of course, the stock is up 78 per cent year to date.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Immutep raises $100m and signs with Merck on ‘blockbuster’ drug
Shares in the oncology therapy hopeful have risen some 45 per cent in the last 12 months as the company nears the commercialisation of its drug, Efti.
- Kylar Loussikian
BCAL Diagnostics closes oversubscribed raise; Ellerston tops up
Sources said BCAL has initially sought $5 million, but was able to raise twice that amount based on the demand.
- Sarah Thompson, Kanika Sood and Emma Rapaport
May
This is how much saturated fat you can ‘get away’ with eating
A study shows that processes that occur in your heart and blood are the biggest driver in how our bodies use different fats as fuel.
- Boudicca Fox-Leonard
Chemist Warehouse-bound Sigma gets first strike on pay
The drug wholesaler, which is seeking to merge with Chemist Warehouse, will get news on the deal from the ACCC in mid-June.
- Carrie LaFrenz
Fisher & Paykel leaves pandemic behind as respirator demand grows
Earlier this year, Vertium Asset Management’s Jason Teh put the New Zealand-based group on his list of turnaround prospects. Issues at its rival are helping.
- Kylar Loussikian
Healthscope is a fiasco for private debt funds – and their unitholders
In these situations, unitholders typically find out after the fact just how stressed the positions are.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Healius to sell $650m X-ray and ultrasound division after UBS review
The struggling pathology company told investors it had engaged advisers to sell Lumus Imaging as it focuses on reinvigorating its core pathology business.
- Simon Evans
Five V Capital signs $200m-plus Habit Health acquisition
The Sydney-based private equity firm has picked up Livingbridge’s portfolio company for a mid-$200 million figure.
- Sarah Thompson, Kanika Sood and Emma Rapaport
